Peptide Pipeline: China's Fentanyl Makers Shift Focus Amid Crypto Boom
China's fentanyl pipeline is shifting towards peptides, according to Chainalysis, as blockchain analysis reveals that one of the same Chinese manufacturers responsible for producing opioids like fentanyl is driving online peptide sales. The FDA's Pharmacy Compounding Advisory Committee will meet this Thursday and Friday to discuss adding seven peptides to the Section 503A Bulks List, which determines what drugs medical professionals can use to create custom prescriptions.
The same manufacturer has reaped approximately $27 million in the first quarter of 2026 through crypto sales, a 150% increase from the previous quarter. This pivot is attributed to a business decision, according to Chainalysis senior intelligence analyst Sara Graham. The FDA previously warned against using unapproved GLP-1 drugs and other custom drugs due to concerns over counterfeit products lacking safety and quality standards.
Nuritas CEO Nora Khaldi expressed concern over the risks people are taking by using unapproved peptides, stating 'No matter how great a molecule is, the risk you're taking by using and taking it when you don't know the quality.… It's mind-blowing.'